Publication Name	World Journal of Clinical Cases
Manuscript ID	99043
Country	Egypt

Received	2024-07-11 21:32
Peer-Review Started	2024-07-11 21:32
To Make the First Decision
Return for Revision	2024-11-15 07:15
Revised	2024-11-18 07:51
Second Decision	2024-12-02 02:45
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-12-02 07:26
Articles in Press	2024-12-02 07:26
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-12-09 00:24
Publish the Manuscript Online	2024-12-12 07:29

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Atezolizumab and bevacizumab combination in advanced hepatocellular carcinoma patients: The imperative for safety assessment studies
Manuscript Source	Invited Manuscript
All Author List	Mina Tharwat, Ahmed Tawheed and Mohamed El-Kassas
Funding Agency and Grant Number
Corresponding Author	Mohamed El-Kassas, MD, Professor, Department of Endemic Medicine, Faculty of Medicine, Helwan University, Ain Helwan, Cairo 11795, Egypt. m_elkassas@hq.helwan.edu.eg
Key Words	Hepatocellular carcinoma; Atezolizumab; Bevacizumab; Hemorrhage; Side effects
Core Tip	In this article, we comment on the case report by Park et al, published in the recently reporting a fatal intra-tumoral hemorrhage in a patient with hepatocellular carcinoma following successful treatment with atezolizumab/bevacizumab. Multiple predictive factors have been reported to be associated with such condition. They can be categorized as either patient-related (age, systemic hypertension, and use of anticoagulants), liver disease-related (degree of liver decompensation and thrombocytopenia), or tumor-related (portal vein thrombosis). However, future studies are required to assess the long-term safety of this combination in patients with hepatocellular carcinoma.
Publish Date	2024-12-12 07:29
Citation	<p>Tharwat M, Tawheed A, El-Kassas M. Atezolizumab and bevacizumab combination in advanced hepatocellular carcinoma patients: The imperative for safety assessment studies. <i>World J Clin Cases</i> 2025; 13(9): 99043</p>
URL	https://www.wjgnet.com/2307-8960/full/v13/i9/99043.htm
DOI	https://dx.doi.org/10.12998/wjcc.v13.i9.99043

Full Article (PDF)	WJCC-13-99043-with-cover.pdf
Manuscript File	99043_Auto_Edited_020528.docx
Answering Reviewers	99043-answering-reviewers.pdf
Audio Core Tip	99043-audio.m4a
Conflict-of-Interest Disclosure Form	99043-conflict-of-interest-statement.pdf
Copyright License Agreement	99043-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	99043-non-native-speakers.pdf
Peer-review Report	99043-peer-reviews.pdf
Scientific Misconduct Check	99043-scientific-misconduct-check.png
Scientific Editor Work List	99043-scientific-editor-work-list.pdf
CrossCheck Report	99043-crosscheck-report.pdf